Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: A system for selecting an expert and receiving expert evaluation data comprising: a computer having access to a database comprising subject matter expert data; where said computer is programmed to perform computer-implemented operations comprising: receiving solution requirement data; accessing said database comprising subject matter expert data and comparing said solution requirement data to said subject matter expert data; selecting at least one subject matter expert; outputting solution requirement data to said subject matter expert; receiving solution option data based on said subject matter expert's evaluation; and wherein said solution requirement data comprises job requirement data and solution option data comprises candidate evaluation data comprising interaction between said subject matter expert and a candidate.

Abstract: Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R—R1, where R is phenyl, where R1 is (CH2)n—Se—C(?NH)—NH2, where R2 is (CH2)n—Se—C(?NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Abstract: A system for selecting an expert and receiving expert evaluation data comprising: a computer having access to a database comprising subject matter expert data; where said computer is programmed to perform computer-implemented operations comprising: receiving user input comprising solution requirement data; accessing said database comprising subject matter expert data and comparing said solution requirement data to said subject matter expert data; selecting at least one subject matter expert; outputting solution requirement data to said subject matter expert; and receiving solution option data based on said subject matter expert's evaluation.

Abstract: Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R-R1, where R is phenyl, where R1 is (CH2)nSe—C(?NH)—NH2, where R2 is (CH2)nSe—C(?NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Abstract: The present invention is directed to a method of treating cancer, particularly canine hemangiosarcoma. The method includes the continuous and regular administration of a formulation including a histone deacetylase inhibitor as part of the standard canine diet. The preferred histone deacetylase inhibitor is SAHA. The formulation is administered following splenectomy to prevent tumor recurrence.

Abstract: Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: where R is phenyl, where R1 is (CH2)n—Se—C(?NH)—NH2, where R2 is (CH2)n—Se—C(?NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Abstract: Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.

Abstract: The present invention is directed to a method of treating cancer, particularly canine hemangiosarcoma. The method includes the continuous and regular administration of a formulation including a histone deacetylase inhibitor as part of the standard canine diet. The preferred histone deacetylase inhibitor is SAHA. The formulation is administered following splenectomy to prevent tumor recurrence.